Alterations in the fibroblast growth factor receptor 1 (FGFR1) have been linked to the development and progression of several types of cancer, including breast, lung, gastric, bladder, and ovarian cancers, and is associated with poor prognosis and resistance to chemotherapy [1,2,3]. This evidence concerns the gene FGFR1 and ovarian carcinoma.